The heightened scrutiny of pharmacy benefit managers by federal agencies continues to pick up steam. Late last week, the Federal Trade Commission changed course on previous statements opposing state legislation that would boost transparency over the entities that manage prescription drug benefits.

"We want to make sure that prior statements are not being relied on in a way that could be impeding ongoing efforts at the state level or even at the federal level to be examining the practices of these PBMs and in some cases, requiring certain types of transparency or disclosure requirements," FTC Chair Lina Khan said.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.